Big Pharma Split Corp Class A (PRM) — Long-term Investment Intensity
Big Pharma Split Corp Class A (PRM) has a Long-term Investment Intensity of 95.4% as of December 2025. Long-term investments of CA$30.38 Million represent 95.4% of total assets of CA$31.84 Million. A higher ratio indicates a company with significant capital committed to long-duration strategic positions. Check PRM asset liquidity ratio to evaluate the company's liquid asset resilience ratio.
LT Investment Intensity
Long-term Investments
Total Assets
Country
Big Pharma Split Corp Class A Long-term Investment Intensity (2017–2025)
This chart shows how Big Pharma Split Corp Class A's Long-term Investment Intensity has evolved across 8 annual periods from 2017 to 2025. As of December 2025, the intensity stands at 95.4%, reflecting long-term investments of CA$30.38 Million against total assets of CA$31.84 Million CAD. For the complete balance sheet picture, see PRM total assets.
Annual Long-term Investment Intensity for Big Pharma Split Corp Class A (2017–2025)
The table below presents the year-by-year Long-term Investment Intensity for Big Pharma Split Corp Class A from 2017 to 2025, covering 8 annual filings. Each row shows total assets, long-term investments, the intensity percentage, and the change in percentage points compared to the prior year. Read PRM total liabilities for a breakdown of total debt and financial obligations.
| Year | LT Investment Intensity | LT Investments (CAD) | Total Assets | Change (pp) |
|---|---|---|---|---|
| 2025 | 95.4% | CA$30.38 Million | CA$31.84 Million | ▼ -0.3 pp |
| 2024 | 95.7% | CA$25.17 Million | CA$26.30 Million | ▼ -3.2 pp |
| 2023 | 98.9% | CA$26.25 Million | CA$26.53 Million | ▲ +36.9 pp |
| 2022 | 62.1% | CA$24.27 Million | CA$39.10 Million | ▼ -33.5 pp |
| 2021 | 95.5% | CA$36.13 Million | CA$37.81 Million | ▼ -2.3 pp |
| 2020 | 97.9% | CA$22.45 Million | CA$22.93 Million | ▼ -0.7 pp |
| 2018 | 98.6% | CA$33.14 Million | CA$33.63 Million | ▲ +4.3 pp |
| 2017 | 94.3% | CA$30.63 Million | CA$32.49 Million | — |